BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoshimatsu K, Ishibashi K, Koda K, Yokomizo H, Oda N, Oshiro M, Kato H, Oya M, Nakajima H, Ooki S, Maekawa H, Matsunami T, Tsubaki M, Yamada T, Kobayashi M, Tanakaya K, Yokoyama M, Ishida H. A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy. Surg Today 2019;49:498-506. [DOI: 10.1007/s00595-019-1771-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Cusano E, Wong C, Taguedong E, Vaska M, Abedin T, Nixon N, Karim S, Tang P, Heng DYC, Ezeife D. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Curr Oncol 2021;28:4894-928. [PMID: 34898590 DOI: 10.3390/curroncol28060412] [Reference Citation Analysis]
2 Hata T, Hagihara K, Tsutsui A, Akamatsu H, Ohue M, Shingai T, Tei M, Ikenaga M, Kim HM, Osawa H, Takemoto H, Konishi K, Uemura M, Matsuda C, Mizushima T, Murata K, Ohno Y, Doki Y, Eguchi H. Administration Method of Adjuvant Tegafur-Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study. Oncologist 2021;26:e735-41. [PMID: 33604941 DOI: 10.1002/onco.13724] [Reference Citation Analysis]
3 Kumamoto K, Nakachi Y, Mizuno Y, Yokoyama M, Ishibashi K, Kosugi C, Koda K, Kobayashi M, Tanakaya K, Matsunami T, Eguchi H, Okazaki Y, Ishida H. Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy. Oncol Lett 2019;18:1388-94. [PMID: 31423202 DOI: 10.3892/ol.2019.10437] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ren JQ, Zhang HS, Zhang LH, Zhong QG, Wu F, Wang BL, Liu SJ. Optimal adjuvant chemotherapy completion time for stage III colon cancer: a cohort study. J Gastrointest Oncol 2021;12:1558-67. [PMID: 34532110 DOI: 10.21037/jgo-21-317] [Reference Citation Analysis]
5 Ohta R, Yamada T, Hara K, Iwai T, Tanakaya K, Ishibashi K, Yoshimatsu K, Kosugi C, Tsubaki M, Nakajima H, Oya M, Yoshida H, Koda K, Ishida H. Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan. Int J Clin Oncol 2020;25:2075-82. [PMID: 32785799 DOI: 10.1007/s10147-020-01763-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Takeshita E, Ishibashi K, Koda K, Oda N, Yoshimatsu K, Sato Y, Oya M, Yamaguchi S, Nakajima H, Momma T, Maekawa H, Tsubaki M, Yamada T, Kobayashi M, Tanakaya K, Ishida H. The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study. Surg Today 2021;51:1309-19. [PMID: 33586034 DOI: 10.1007/s00595-021-02230-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]